Brind.

ANI Pharmaceuticals tested Iluvien in a clinical trial for Diabetic Macular Oedema, comparing it against aflibercept.

2 reports, 2 independent Updated Jul 24
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

ANI Pharmaceuticals tested Iluvien in a clinical trial for Diabetic Macular Oedema, comparing it against aflibercept.

Who's involved

What this event is mainly about
ANI Pharmaceuticals (United States)

How it developed

Newest first. Tap a step to see who reported it.
  1. ANI Pharmaceuticals tested Iluvien against aflibercept for Diabetic Macular Oedema.1 source
  2. ANI presented trial results for Iluvien in Diabetic Macular Oedema.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Clinical Trials ArenaANI Pharmaceuticals reports outcomes from diabetic macular oedema trial ANI Pharmaceuticals has disclosed the outcomes of its randomised NEW DAY trial, assessing Iluvien 0.19mg, in people with diabet
  • GlobeNewswireANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME) Trial evaluated number of supplemental injections needed for the tr